Log in to search using one of your social media accounts:

 

Alpha-1 Antitrypsin Deficiency (Symptoms, Treatment, LIfe Expectancy)
Title: Alpha-1 Antitrypsin Deficiency (Symptoms, Treatment, LIfe Expectancy)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 6/19/2017 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - June 19, 2017 Category: Respiratory Medicine Source Type: news

How Common is α -1-Antitrypsin Deficiency?
Discussion α-1-Antitrypsin Deficiency (A1AT) is a common single-gene mutation disease that is homozygous recessive. The normal allele is called M and the most common abnormal allele is Z. There are other alleles though. The gene codes for one of the primary protease inhibitors in the serum, thus those who are homozygous for the Z gene are sometimes referred to as “PIZZ” or “PIZ.” α-1-Antitrypsin is found in all body tissues but is especially important in the serum and lung. As noted it is one of the primary neutrophil protease inhibitors in the serum, and acts to neutralize these enzymes...
Source: PediatricEducation.org - April 24, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

23andMe is back: FDA allows marketing of genetic health risk tests
[Image courtesy of 23andMe]FDA this month allowed genetic testing company 23andMe to market genetic health risk tests for 10 diseases and conditions including Parkinson’s disease and late-onset Alzheimer’s disease. The de novo premarket review authorization, announced April 6, also included celiac disease, which results in the inability to digest gluten; alpha-1 antitrypsin deficiency, which raises the risk of lung and liver disease; early-onset primary dystonia, a movement disorder; factor XI deficiency, a blood clotting disorder; Gaucher disease type 1, a disorder involving organs and tissue; glucose-6-p...
Source: Mass Device - April 21, 2017 Category: Medical Equipment Authors: Chris Newmarker Tags: Business/Financial News Diagnostics Food & Drug Administration (FDA) Genomics Molecular Diagnostics News Well Regulatory/Compliance 23andme 23andMe Inc. MedTech Source Type: news

Arrowhead begins Phase II trial of ARC-AAT to treat AATD
US-based biopharmaceutical firm Arrowhead has commenced its Phase II clinical trial of ARC-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency (AATD). (Source: Drug Development Technology)
Source: Drug Development Technology - September 6, 2016 Category: Pharmaceuticals Source Type: news

Kamada reports positive top-line results of US Phase II trial of inhaled AAT therapy for AATD
Israeli-based therapeutics company Kamada has reported positive top-line results of its US Phase II clinical trial of inhaled Alpha-1 Antitrypsin (AAT) therapy to treat Alpha-1 Antitrypsin Deficiency (AATD). (Source: Drug Development Technology)
Source: Drug Development Technology - August 31, 2016 Category: Pharmaceuticals Source Type: news

Investigational Gene-Based Therapy for Alpha-1 Antitrypsin (AAT) Deficiency Demonstrates Durable Response at Five Years
Research led by scientists from the University of Massachusetts Medical School presented at the American Society of Gene and Cell Therapy (ASGTC) Annual Meeting WASHINGTON, May 05, 2016 -- (Healthcare Sales & Marketing Network) -- Researchers from the U... BiopharmaceuticalsApplied Genetic Technologies, gene therapy, Alpha-1 Antitrypsin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 5, 2016 Category: Pharmaceuticals Source Type: news

Progress Noted in Treatment of Several Common Liver DiseasesProgress Noted in Treatment of Several Common Liver Diseases
Dr William Balistreri provides an overview of the latest data on such disorders as alpha-1 antitrypsin deficiency, drug-induced liver injury, and parenteral nutrition-associated cholestasis. Medscape Gastroenterology (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - April 8, 2016 Category: Transplant Surgery Tags: Gastroenterology Commentary Source Type: news

Kamada starts Alpha-1 Antitrypsin phase 2 clinical trial to prevent lung transplant rejection
Kamada has started a phase 2 clinical trial with its proprietary drug Alpha-1 Antitrypsin (AAT) for preventing rejection in lung transplants, as part of a collaboration with Baxalta. (Source: Drug Development Technology)
Source: Drug Development Technology - April 6, 2016 Category: Pharmaceuticals Source Type: news

Fibrinogen and Alpha 1-Antitrypsin in COPD ExacerbationsFibrinogen and Alpha 1-Antitrypsin in COPD Exacerbations
How are fibrinogen and Alpha 1-antitrypsin associated with exacerbations in COPD? Thorax (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - November 25, 2015 Category: Pathology Tags: Pulmonary Medicine Journal Article Source Type: news

Inhibitor Slows Lung Decline in Inherited EmphysemaInhibitor Slows Lung Decline in Inherited Emphysema
Replacement therapy can lessen lung decline in patients with alpha-1 antitrypsin deficiency who develop emphysema, and might be of benefit to emphysema patients without the genetic disorder. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 29, 2015 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Alnylam begins ALN-AAT’s Phase I / II trial for alpha-1 liver disease
Alnylam Pharmaceuticals has started the Phase I / II clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) to treat AAT deficiency-associated liver disease (alpha-1 liver disea… (Source: Drug Development Technology)
Source: Drug Development Technology - July 27, 2015 Category: Pharmaceuticals Source Type: news

Novel therapeutic strategy for single gene disorders delivers RNA that encodes the missing protein
(Mary Ann Liebert, Inc./Genetic Engineering News) Researchers have demonstrated the feasibility of delivering an RNA that encodes for the protein alpha-1-antitrypsin -- which is missing or nonfunctional in the genetic disorder AAT deficiency -- into cells in the laboratory, enabling the cells to produce highly functional AAT. This innovative approach to treating single gene disorders such as AAT deficiency offers and safe, simpler, and more cost-effective alternative to gene therapy or protein replacement, according to the authors of the study published in Nucleic Acid Therapeutics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 27, 2015 Category: Global & Universal Source Type: news

Arrowhead doses first patient in Part B of Phase I trial of ARC-AAT to treat AATD
US-based Arrowhead Research has dosed the first patient in Part B of a Phase I clinical trial of its RNAi-based drug candidate ARC-AAT to treat liver disease associated with the rare genetic disorder alpha-1 antitrypsin deficiency (AATD). (Source: Drug Development Technology)
Source: Drug Development Technology - July 2, 2015 Category: Pharmaceuticals Source Type: news

iPSC model helps to better understand genetic lung/liver disease
Using patient-derived stem cells known as induced pluripotent stem cells (iPSC) to study the genetic lung/liver disease called alpha-1 antitrypsin deficiency, researchers have for the first time created a disease signature that may help explain how abnormal protein leads to liver disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 2, 2015 Category: Science Source Type: news

Liver Disease From Alpha-1-Antitrypsin DeficiencyLiver Disease From Alpha-1-Antitrypsin Deficiency
What therapeutic options for liver failure in patients with alpha-1-antitrypsin deficiency are in the pipeline? Medscape Internal Medicine (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 5, 2015 Category: Gastroenterology Tags: Gastroenterology Ask the Expert Source Type: news

Revised Article-Alpha-1 Antitrypsin Deficiency
Alpha-1 antitrypsin deficiency, or AAT deficiency, is a condition that raises your risk for lung disease (especially if you smoke) and other diseases. (Source: National Heart, Lung, and Blood Institute Health Topics)
Source: National Heart, Lung, and Blood Institute Health Topics - October 27, 2014 Category: Consumer Health News Source Type: news

Inflammatory Cytokine Response to Exercise in COPD PatientsInflammatory Cytokine Response to Exercise in COPD Patients
Do alpha-1-antitrypsin-deficient (AATD) COPD patients exhibit reduced inflammation compared to non-AATD COPD patients? BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2014 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Kamada begins Phase I/II trial of Glassia to treat graft-versus-host disease
Israel-based Kamada has initiated a US-based proof-of-concept (POC) trial with its proprietary, highly-purified, liquid form of human Alpha-1 Antitrypsin (AAT) 'Glassia' for the treatment of graft-versus-host disease (GVHD). (Source: Drug Development Technology)
Source: Drug Development Technology - April 3, 2014 Category: Pharmaceuticals Source Type: news

Alpha-1 Antitrypsin Deficiency
Title: Alpha-1 Antitrypsin DeficiencyCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 4/1/2014 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - April 1, 2014 Category: Respiratory Medicine Source Type: news

Kamada begins Phase II/III Glassia study for treatment of type 1 diabetes
Israel-based Kamada has started a Phase II/III clinical study of its proprietary human Alpha-1 Antitrypsin (AAT) 'Glassia' for the treatment of newly diagnosed paediatric patients with type 1 diabetes (T1D). (Source: Drug Development Technology)
Source: Drug Development Technology - March 7, 2014 Category: Pharmaceuticals Source Type: news

Study Demonstrating Pancreatic Islet Xenograft Survival With Kamada's AAT
Kamada Ltd. (Nasdaq and TASE: KMDA) have announced that favorable results from a preclinical study analyzing the effects of the Company's human Alpha-1 Antitrypsin (AAT), Glassia, in inter-species islet graft transplantation were published in PLOS One, an open-access peer-reviewed publication. The article is entitled "Pancreatic Islet Xenograft Survival in Mice Is Extended by a Combination of Alpha-1-Antitrypsin and Single Dose Anti-CD4/CD8 Therapy." The study was funded by the Juvenile Diabetes Research Foundation and performed by the team of Eli C. Lewis, Ph.D... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 12, 2013 Category: Consumer Health News Tags: Transplants / Organ Donations Source Type: news

Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency
(American Thoracic Society) Treatment with an Alpha-1 proteinase inhibitor, a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency, a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 21, 2013 Category: Global & Universal Source Type: news

Being young, free, and single no boost in COPD
Research shows that patients with alpha-1 antitrypsin deficiency-related chronic obstructive pulmonary disease experience more anxiety the younger they are. (Source: MedWire News - Respiratory)
Source: MedWire News - Respiratory - May 11, 2013 Category: Respiratory Medicine Source Type: news

Revised Article-Alpha-1 Antitrypsin Deficiency
Alpha-1 antitrypsin deficiency, or AAT deficiency, is a condition that raises your risk for certain types of lung disease, especially if you smoke. (Source: National Heart, Lung, and Blood Institute Health Topics)
Source: National Heart, Lung, and Blood Institute Health Topics - March 5, 2010 Category: Consumer Health News Source Type: news